CalciMedica, Inc. (CALC)

OTCMKTS: CALC · Delayed Price · USD
4.160
0.00 (0.00%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Company Description

CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs.

Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases.

Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury.

The company is based in La Jolla, California.

CalciMedica, Inc.
Country Canada
Founded 2011
Industry Biotechnology
Sector Healthcare
Employees 14
CEO Dr. A. Rachel Leheny Ph.D.

Contact Details

Address:
505 Coast Boulevard South, Suite 307
La Jolla, California 92037
United States
Phone 858-952-5500
Website calcimedica.com

Stock Details

Ticker Symbol CALC
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001534133
ISIN Number US38942Q2021
Employer ID 45-2120079
SIC Code 2834

Key Executives

Name Position
Dr. A. Rachel Leheny Ph.D. Chief Executive Officer and Director
Eric W. Roberts Chief Business Officer and Vice Chairman of the Board
Michael J. Dunn MBA President and Chief Operating Officer
Dr. Anjana Rao Ph.D. Co-Founder and Scientific Advisor
Dr. Patrick Hogan Ph.D. Co-Founder and Scientific Advisor
Dr. Stefan Feske M.D. Co-Founder and Scientific Advisor
Dr. Kenneth A. Stauderman Ph.D. Co-Founder and Chief Scientific Officer
Daniel E. Geffken M.B.A. Interim Chief Financial Officer
Cindy Reiedenberg Accountant
John M. Dunn J.D. General Counsel

Latest SEC Filings

Date Type Title
Mar 28, 2024 8-K Current Report
Feb 13, 2024 8-K Current Report
Feb 9, 2024 EFFECT Notice of Effectiveness
Feb 8, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Feb 8, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 7, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 6, 2024 UPLOAD Filing
Feb 5, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Feb 1, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 1, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals